REGENXBIO Inc.
RGNX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$6.68
KIRA · Stoqly’s AI analyst, in plain words
- REGENXBIO Inc. had $170M of revenue in fiscal 2025, up 104.5% on the year before. Over five years, revenue changed +2.0% a year on average.
- Its operating margin was −94.6%, up 185.5 pts: of every 100 in sales, about −95 is left after running the business.
- REGENXBIO Inc. lost $194M in fiscal 2025.
- Free cash flow was −$126M in fiscal 2025, −74.1% of revenue.
Market cap
$354M
P/E
—
Revenue
$170M
Net income
−$194M
Free cash flow
−$126M
Operating margin
−94.6%
REGENXBIO Inc. in 30 seconds · fiscal 2025
Are sales growing?
+104.5%
Yes. Sales grew 104.5% last year.
Does it make a profit?
−113.8%
No. It lost money last year.
Does profit turn into cash?
−74.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What REGENXBIO Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- REGENXBIO Inc.
- CIK
- 0001590877
REGENXBIO Inc. · RGNX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $470M | $113M | $90.2M | $83.3M | $170M |
| Revenue growth | 204.3% | −76.0% | −19.9% | −7.7% | 104.5% |
| Gross margin | 89.0% | 51.6% | 58.8% | 59.7% | — |
| Operating margin | 34.0% | −233.2% | −297.1% | −280.0% | −94.6% |
| Net income | $128M | −$280M | −$263M | −$227M | −$194M |
| Net margin | 27.2% | −248.7% | −292.0% | −272.5% | −113.8% |
| Diluted EPS | $2.91 | −$6.50 | −$6.02 | −$4.59 | −$3.76 |
| Cash | |||||
| Cash from operations | $219M | −$207M | −$218M | −$173M | −$124M |
| Capital expenditure | $84.2M | $30.7M | $10.0M | $2.4M | $2.4M |
| Free cash flow | $135M | −$238M | −$228M | −$176M | −$126M |
| FCF margin | 28.6% | −211.3% | −253.1% | −210.7% | −74.1% |
| Share count change | 17.8% | −1.7% | 1.3% | 13.2% | 4.2% |
| Debt and strength | |||||
| Cash and short-term investments | $457M | $365M | $275M | $235M | $230M |
| Shareholders' equity | $764M | $516M | $312M | $260M | $103M |
| Current ratio | 4.0x | 3.2x | 2.6x | 2.7x | 2.4x |
| Interest coverage | 6.1x | −11.3x | −39.1x | −18.4x | −3.6x |
| Returns and quality | |||||
| Return on equity | 22.4% | −43.8% | −63.7% | −79.5% | −107.0% |
| Return on tangible equity | 16.7% | −54.3% | −84.5% | −87.5% | −188.7% |
| Piotroski F-score | 6 | 2 | 3 | 4 | 3 |
| Altman Z'' | 5.1 | 0.1 | −3.6 | −6.1 | −7.8 |
Insiders bought, 12 months
$0.9M
1 insider
Insiders sold, 12 months
$0.9M
1 insider
Of sales under plans
100%
$0.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
REGENXBIO Inc. · RGNX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.68 a share, the company is worth $354M.
Source: SEC EDGAR XBRL filings (CIK 0001590877). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.